Amori, Renee E., Joseph Lau, and Anastassios G. Pittas. ‘Efficacy and Safety of Incretin Therapy in Type 2 Diabetes’. JAMA 298.2 (2007): n. pag. Web.
Amy Kennedy. ‘Does Exercise Improve Glycaemic Control in Type 1 Diabetes? A Systematic Review and Meta-Analysis’. PLoS ONE 8.3 (2013): n. pag. Web. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598953/>.
Anderson, Bob, Martha Funnell, and American Diabetes Association. The Art of Empowerment: Stories and Strategies for Diabetes Educators. 2nd ed. Alexandria, Va: American Diabetes Association, 2005. Print.
Anthony H. Barnett, Jenny Grice. New Mechanisms in Glucose Control. BMJ Books; 1 edition, 2013. Web. <http://ezproxy.lib.le.ac.uk/login?url=http://lib.myilibrary.com?id=478133>.
‘[ARCHIVED CONTENT] Medicines Management: Everybody’s Business : Department of Health - Publications and Statistics’. Web. <http://webarchive.nationalarchives.gov.uk/20080205142458/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_082200>.
Ashwell, S. G. et al. ‘Improved Glycaemic Control with Insulin Glargine plus Insulin Lispro: A Multicentre, Randomized, Cross-over Trial in People with Type 1 Diabetes’. Diabetic Medicine 23.3 (2006): 285–292. Web.
Atkinson, M. A. ‘The Pathogenesis and Natural History of Type 1 Diabetes’. Cold Spring Harbor Perspectives in Medicine 2.11 (2012): a007641–a007641. Web.
Avery, L. et al. ‘Changing Physical Activity Behavior in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Behavioral Interventions’. Diabetes Care 35.12 (2012): 2681–2689. Web.
Bailey, Clifford J et al. ‘Effect of Dapagliflozin in Patients with Type 2 Diabetes Who Have Inadequate Glycaemic Control with Metformin: A Randomised, Double-Blind, Placebo-Controlled Trial’. The Lancet 375.9733 (2010): 2223–2233. Web.
Barry, Vaughn W. et al. ‘Fitness vs. Fatness on All-Cause Mortality: A Meta-Analysis’. Progress in Cardiovascular Diseases 56.4 (2014): 382–390. Web.
Bennett, Wendy L. et al. ‘Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations’. Annals of Internal Medicine 154.9 (2011): n. pag. Web.
Bethel, M. Angelyn et al. ‘Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS)’. Diabetes Care (2017): n. pag. Web.
Beverley M Shields. ‘Can Clinical Features Be Used to Differentiate Type 1 from Type 2 Diabetes? A Systematic Review of the Literature’. BMJ Open 5.11 (2015): n. pag. Web. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636628/?report=classic>.
Birkeland, Kåre I. ‘Hyperglycaemia in Pregnancy: Still a Lot to Learn’. The Lancet Diabetes & Endocrinology 3.10 (2015): 752–753. Web.
Bretzel, Reinhard G et al. ‘Once-Daily Basal Insulin Glargine versus Thrice-Daily Prandial Insulin Lispro in People with Type 2 Diabetes on Oral Hypoglycaemic Agents (APOLLO): An Open Randomised Controlled Trial’. The Lancet 371.9618 (2008): 1073–1084. Web.
Brown, Julie et al. ‘Lifestyle Interventions for the Treatment of Women with Gestational Diabetes’. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd, 1996. Web. <http://doi.wiley.com/10.1002/14651858.CD011970.pub2>.
Buse, J. B. et al. ‘DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks’. Diabetes Care 33.6 (2010): 1255–1261. Web.
Buse, John B et al. ‘Liraglutide Once a Day versus Exenatide Twice a Day for Type 2 Diabetes: A 26-Week Randomised, Parallel-Group, Multinational, Open-Label Trial (LEAD-6)’. The Lancet 374.9683 (2009): 39–47. Web.
Buse, John B. et al. ‘Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes’. Annals of Internal Medicine 154.2 (2011): n. pag. Web.
Capehorn, M. et al. ‘Challenges Faced by Physicians When Discussing the Type 2 Diabetes Diagnosis with Patients: Insights from a Cross-National Study (IntroDia )’. Diabetic Medicine (2017): n. pag. Web.
Carver, Catherine. ‘Insulin Treatment and the Problem of Weight Gain in Type 2 Diabetes’. The Diabetes Educator 32.6 (2006): 910–917. Web.
Celia G. Walker. ‘Modelling the Interplay between Lifestyle Factors and Genetic Predisposition on Markers of Type 2 Diabetes Mellitus Risk’. PLoS ONE 10.7 (2015): n. pag. Web. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496090/>.
Chatterjee, Sudesna, and Melanie Davies. ‘Type 2 Diabetes: Recent Advances in Diagnosis and Management’. Prescriber 26.10 (2015): 15–21. Web.
Chimen, M. et al. ‘What Are the Health Benefits of Physical Activity in Type 1 Diabetes Mellitus? A Literature Review’. Diabetologia 55.3 (2012): 542–551. Web.
Choudhary, Pratik et al. ‘Islet Cell Transplantation: Current Status in the UK (2012)’. Practical Diabetes 29.7 (2012): 280–285. Web.
Copeland, K. C. et al. ‘Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents’. PEDIATRICS 131.2 (2013): 364–382. Web.
Courtney, Hamish et al. ‘Long-Term Management of Type 2 Diabetes with Glucagon-like Peptide-1 Receptor Agonists’. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Volume 10 (2017): 79–87. Web.
Crasto, Winston, Janet Jarvis, and Melanie J. Davies. Handbook of Insulin Therapies. Switzerland: Adis, 2016. Web. <http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745>.
---. Handbook of Insulin Therapies. Switzerland: Adis, 2016. Web. <http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745>.
---. Handbook of Insulin Therapies. Switzerland: Adis, 2016. Web. <http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745>.
---. Handbook of Insulin Therapies. Switzerland: Adis, 2016. Web. <http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745>.
---. Handbook of Insulin Therapies. Switzerland: Adis, 2016. Web. <http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745>.
---. Handbook of Insulin Therapies. Switzerland: Adis, 2016. Web. <http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745>.
Daly, H et al. ‘Development of a Self-Management Education Module for Those with Type 2 Diabetes on Injectable Therapies’. Practical Diabetes 32.8 (2015): 305–310a. Web.
Davies, M., F. Storms, et al. ‘Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of Two Treatment Algorithms Using Insulin Glargine’. Diabetes Care 28.6 (2005): 1282–1288. Web.
Davies, M., D. Dahl, et al. ‘Introduction of Biosimilar Insulins in Europe’. Diabetic Medicine 34.10 (2017): 1340–1353. Web.
Davies, M J et al. ‘Effectiveness of the Diabetes Education and Self Management for Ongoing and Newly Diagnosed (DESMOND) Programme for People with Newly Diagnosed Type 2 Diabetes: Cluster Randomised Controlled Trial’. BMJ 336.7642 (2008): 491–495. Web.
Davies, Melanie J., and Sudesna Chatterjee. ‘Trial Watch: Insulin Initiation for Type 2 Diabetes Mellitus in Primary Care’. Nature Reviews Endocrinology 13.6 (2017): 317–318. Web.
Deacon, C. F., and H. E. Lebovitz. ‘Comparative Review of Dipeptidyl Peptidase-4 Inhibitors and Sulphonylureas’. Diabetes, Obesity and Metabolism 18.4 (2016): 333–347. Web.
Dhatariya, K. K., C. Skedgel, and R. Fordham. ‘The Cost of Treating Diabetic Ketoacidosis in the UK: A National Survey of Hospital Resource Use’. Diabetic Medicine 34.10 (2017): 1361–1366. Web.
Diamant, Michaela et al. ‘Once Weekly Exenatide Compared with Insulin Glargine Titrated to Target in Patients with Type 2 Diabetes (DURATION-3): An Open-Label Randomised Trial’. The Lancet 375.9733 (2010): 2234–2243. Web.
---. ‘Once Weekly Exenatide Compared with Insulin Glargine Titrated to Target in Patients with Type 2 Diabetes (DURATION-3): An Open-Label Randomised Trial’. The Lancet 375.9733 (2010): 2234–2243. Web.
Dungan, Kathleen M et al. ‘Once-Weekly Dulaglutide versus Once-Daily Liraglutide in Metformin-Treated Patients with Type 2 Diabetes (AWARD-6): A Randomised, Open-Label, Phase 3, Non-Inferiority Trial’. The Lancet 384.9951 (2014): 1349–1357. Web.
‘Effects of Intensive Glucose Control on Microvascular Outcomes in Patients with Type 2 Diabetes: A Meta-Analysis of Individual Participant Data from Randomised Controlled Trials- ClinicalKey’. N.p., n.d. Web. <https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213858717301043?returnurl=null&referrer=null>.
‘Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes’. New England Journal of Medicine 375.18 (2016): 1799–1802. Web.
Evans, M. et al. ‘A Review of Modern Insulin Analogue Pharmacokinetic and Pharmacodynamic Profiles in Type 2 Diabetes: Improvements and Limitations’. Diabetes, Obesity and Metabolism 13.8 (2011): 677–684. Web.
Frandsen, C. S. S., and S. Madsbad. ‘Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors as an Add-on to Insulin Treatment in Patients with Type 2 Diabetes: A Review’. Diabetic Medicine 31.11 (2014): 1293–1300. Web.
Funnell, M. M. ‘Overcoming Barriers to the Initiation of Insulin Therapy’. Clinical Diabetes 25.1 (2007): 36–38. Web.
Gallwitz, Baptist et al. ‘2-Year Efficacy and Safety of Linagliptin Compared with Glimepiride in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Randomised, Double-Blind, Non-Inferiority Trial’. The Lancet 380.9840 (2012): 475–483. Web.
Garber, A. J. et al. ‘Attainment of Glycaemic Goals in Type 2 Diabetes with Once-, Twice-, or Thrice-Daily Dosing with Biphasic Insulin Aspart 70/30 (The 1-2-3 Study)’. Diabetes, Obesity and Metabolism 8.1 (2006): 58–66. Web.
Garber, Alan J et al. ‘Insulin Degludec, an Ultra-Longacting Basal Insulin, versus Insulin Glargine in Basal-Bolus Treatment with Mealtime Insulin Aspart in Type 2 Diabetes (BEGIN Basal-Bolus Type 2): A Phase 3, Randomised, Open-Label, Treat-to-Target Non-Inferiority Trial’. The Lancet 379.9825 (2012): 1498–1507. Web.
Garber, Alan J. et al. ‘Premixed Insulin Treatment for Type 2 Diabetes: Analogue or Human?’ Diabetes, Obesity and Metabolism 9.5 (2007): 630–639. Web.
Gough, S. C. L. et al. ‘Insulin Degludec: Overview of a Novel Ultra Long-Acting Basal Insulin’. Diabetes, Obesity and Metabolism 15.4 (2013): 301–309. Web.
Gough, Stephen C.L. ‘A Review of Human and Analogue Insulin Trials’. Diabetes Research and Clinical Practice 77.1 (2007): 1–15. Web.
Grammes, J. et al. ‘Focus Group Study to Identify the Central Facets of Fear of Hypoglycaemia in People with Type 2 Diabetes Mellitus’. Diabetic Medicine (2017): n. pag. Web.
Gray, L. J. et al. ‘Implementation of the Automated Leicester Practice Risk Score in Two Diabetes Prevention Trials Provides a High Yield of People with Abnormal Glucose Tolerance’. Diabetologia 55.12 (2012): 3238–3244. Web.
Gray, L.J. et al. ‘External Validation of Two Diabetes Risk Scores in a Young UK South Asian Population’. Diabetes Research and Clinical Practice 104.3 (2014): 451–458. Web.
Green, Jennifer B. et al. ‘Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes’. New England Journal of Medicine 373.3 (2015): 232–242. Web.
Gururaj Setty, S et al. ‘New Insulins and Newer Insulin Regimens: A Review of Their Role in Improving Glycaemic Control in Patients with Diabetes’. Postgraduate Medical Journal 92.1085 (2016): 152–164. Web.
---. ‘New Insulins and Newer Insulin Regimens: A Review of Their Role in Improving Glycaemic Control in Patients with Diabetes’. Postgraduate Medical Journal 92.1085 (2016): 152–164. Web.
Hadjiconstantinou, Michelle et al. ‘Do Web-Based Interventions Improve Well-Being in Type 2 Diabetes? A Systematic Review and Meta-Analysis’. Journal of Medical Internet Research 18.10 (2016): n. pag. Web.
Hartman, Yvonne A.W. et al. ‘Insulin-Associated Weight Gain in Type 2 Diabetes Is Associated With Increases in Sedentary Behavior’. Diabetes Care 40.9 (2017): e120–e121. Web.
Heinonen, I et al. ‘Sedentary Behaviours and Obesity in Adults: The Cardiovascular Risk in Young Finns Study’. BMJ Open 3.6 (2013): n. pag. Web.
Heller, S. R. et al. ‘Hypoglycaemia with Insulin Aspart: A Double-Blind, Randomised, Crossover Trial in Subjects with Type 1 Diabetes’. Diabetic Medicine 21.7 (2004): 769–775. Web.
Henson, Joseph. ‘Associations of Sedentary Time with Fat Distribution in a High-Risk Population.’ (2014): n. pag. Web. <https://lra.le.ac.uk/handle/2381/32505>.
Hermansen, K. et al. ‘A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes’. Diabetes Care 29.6 (2006): 1269–1274. Web.
Holman, R. R., and R. C. Turner. ‘A Practical Guide to Basal and Prandial Insulin Therapy’. Diabetic Medicine 2.1 (1985): 45–53. Web.
Holman, Rury R. et al. ‘Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes’. New England Journal of Medicine 357.17 (2007): 1716–1730. Web.
Home, P. D. ‘The Pharmacokinetics and Pharmacodynamics of Rapid-Acting Insulin Analogues and Their Clinical Consequences’. Diabetes, Obesity and Metabolism 14.9 (2012): 780–788. Web.
Horvath, Karl et al. ‘Long-Acting Insulin Analogues versus NPH Insulin (Human Isophane Insulin) for Type 2 Diabetes Mellitus’. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd, 1996. Web. <http://doi.wiley.com/10.1002/14651858.CD005613.pub3>.
---. ‘Long-Acting Insulin Analogues versus NPH Insulin (Human Isophane Insulin) for Type 2 Diabetes Mellitus’. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd, 1996. Web. <http://doi.wiley.com/10.1002/14651858.CD005613.pub3>.
Htike, Zin Z. et al. ‘Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes: A Systematic Review and Mixed-Treatment Comparison Analysis’. Diabetes, Obesity and Metabolism 19.4 (2017): 524–536. Web.
---. ‘Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes: A Systematic Review and Mixed-Treatment Comparison Analysis’. Diabetes, Obesity and Metabolism 19.4 (2017): 524–536. Web.
Htike, Zin Zin et al. ‘Glucagon like Peptide-1 Receptor Agonist (GLP-1RA) Therapy in Management of Type 2 Diabetes: Choosing the Right Agent for Individualised Care’. British Journal of Diabetes 16.3 (2016): n. pag. Web.
Inzucchi, Silvio E. et al. ‘Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes’. Diabetes Care 38.1 (2015): 140–149. Web.
Ismail-Beigi, Faramarz. ‘Glycemic Management of Type 2 Diabetes Mellitus’. New England Journal of Medicine 366.14 (2012): 1319–1327. Web.
John M Jakicic. ‘Physical Activity Considerations for the Treatment and Prevention of Obesity’. The American Journal of Clinical Nutrition 82.1 (2005): 226S-229S. Web. <http://ajcn.nutrition.org/content/82/1/226S>.
Johnston, Bradley C. et al. ‘Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults’. JAMA 312.9 (2014): n. pag. Web.
Jones, A. G., and A. T. Hattersley. ‘The Clinical Utility of C-Peptide Measurement in the Care of Patients with Diabetes’. Diabetic Medicine 30.7 (2013): 803–817. Web.
Kamlesh Khunti. ‘Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes’. PLoS ONE 10.9 (2015): n. pag. Web. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556656/?report=classic>.
Kenneth Hodson. ‘Gestational Diabetes: Emerging Concepts in Pathophysiology’. Obstetric Medicine 3.4 (2010): n. pag. Web. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989628/?report=classic>.
Latika Sahu. ‘Comparison of the American Diabetes Association and World Health Organization Criteria for Gestational Diabetes Mellitus and the Outcomes of Pregnancy’. Obstetric Medicine 2.4 (2009): n. pag. Web. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989660/?report=classic>.
Lee, I-Min. ‘Physical Activity and Weight Gain Prevention’. JAMA 303.12 (2010): n. pag. Web.
Leff, D. R., and D. Heath. ‘Surgery for Obesity in Adulthood’. BMJ 339.sep22 1 (2009): b3402–b3402. Web.
Levin, Philip A et al. ‘Glucagon-like Peptide-1 Receptor Agonists: A Systematic Review of Comparative Effectiveness Research’. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Volume 10 (2017): 123–139. Web.
‘Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes’. New England Journal of Medicine 375.18 (2016): 1797–1799. Web.
Mäkimattila, S., K. Nikkilä, and H. Yki-Järvinen. ‘Causes of Weight Gain during Insulin Therapy with and without Metformin in Patients with Type II Diabetes Mellitus’. Diabetologia 42.4 (1999): 406–412. Web.
Marre, M. et al. ‘Liraglutide, a Once-Daily Human GLP-1 Analogue, Added to a Sulphonylurea over 26 Weeks Produces Greater Improvements in Glycaemic and Weight Control Compared with Adding Rosiglitazone or Placebo in Subjects with Type 2 Diabetes (LEAD-1 SU)’. Diabetic Medicine 26.3 (2009): 268–278. Web.
Marso, Steven P., Gilbert H. Daniels, et al. ‘Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes’. New England Journal of Medicine 375.4 (2016): 311–322. Web.
---. ‘Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes’. New England Journal of Medicine 375.4 (2016): 311–322. Web.
Marso, Steven P., Stephen C. Bain, et al. ‘Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes’. New England Journal of Medicine 375.19 (2016): 1834–1844. Web.
Merlin C. Thomas. ‘Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment’. Diabetes Therapy 7.3 (2016): n. pag. Web. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014795/>.
Michael Riddell. ‘Exercise and Glucose Metabolism in Persons with Diabetes Mellitus: Perspectives on the Role for Continuous Glucose Monitoring’. Journal of diabetes science and technology (Online) 3.4 (2009): n. pag. Web. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769951/>.
Min, Se Hee et al. ‘Comparison between SGLT2 Inhibitors and DPP4 Inhibitors Added to Insulin Therapy in Type 2 Diabetes: A Systematic Review with Indirect Comparison Meta-Analysis’. Diabetes/Metabolism Research and Reviews 33.1 (2017): n. pag. Web.
‘Minimizing Hypoglycemia in Diabetes: Table 1’. Diabetes Care 38.8 (2015): 1583–1591. Web.
Mishriky, Basem M., Doyle M. Cummings, and Robert J. Tanenberg. ‘The Efficacy and Safety of DPP4 Inhibitors Compared to Sulfonylureas as Add-on Therapy to Metformin in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis’. Diabetes Research and Clinical Practice 109.2 (2015): 378–388. Web.
---. ‘The Efficacy and Safety of DPP4 Inhibitors Compared to Sulfonylureas as Add-on Therapy to Metformin in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis’. Diabetes Research and Clinical Practice 109.2 (2015): 378–388. Web.
Moreno-Castilla, Cristina, Didac Mauricio, and Marta Hernandez. ‘Role of Medical Nutrition Therapy in the Management of Gestational Diabetes Mellitus’. Current Diabetes Reports 16.4 (2016): n. pag. Web.
Nathan, D. M. et al. ‘Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement from the American Diabetes Association and the European Association for the Study of Diabetes’. Diabetes Care 29.8 (2006): 1963–1972. Web.
Nauck, M. ‘Incretin Therapies: Highlighting Common Features and Differences in the Modes of Action of Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors’. Diabetes, Obesity and Metabolism 18.3 (2016): 203–216. Web.
Nauck, M. A. et al. ‘Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, Compared with the Sulfonylurea, Glipizide, in Patients with Type 2 Diabetes Inadequately Controlled on Metformin Alone: A Randomized, Double-Blind, Non-Inferiority Trial’. Diabetes, Obesity and Metabolism 9.2 (2007): 194–205. Web.
Nauck, Michael et al. ‘Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)’. Diabetes Care 37.8 (2014): 2149–2158. Web.
Nauck, Michael A, and Juris J Meier. ‘The Incretin Effect in Healthy Individuals and Those with Type 2 Diabetes: Physiology, Pathophysiology, and Response to Therapeutic Interventions’. The Lancet Diabetes & Endocrinology 4.6 (2016): 525–536. Web.
Nissen, Steven E., and Kathy Wolski. ‘Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes’. New England Journal of Medicine 356.24 (2007): 2457–2471. Web.
Nolan, Christopher J. et al. ‘Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes’. Diabetes 64.3 (2015): 673–686. Web.
Paul Craddy. ‘Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison’. Diabetes Therapy 5.1 (2014): n. pag. Web. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065303/>.
Persaud, Shanta J., and Peter M. Jones. ‘A Wake-up Call for Type 2 Diabetes?’ New England Journal of Medicine 375.11 (2016): 1090–1092. Web.
‘Postnatal Testing Following Gestational Diabetes- ClinicalKey’. N.p., n.d. Web. <https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213858715003228?returnurl=null&referrer=null>.
‘Professor Kamlesh Khunti - Coding, Classification and Diagnosis of Diabetes’. 4AD. Web. <https://www.youtube.com/watch?v=AhhWTmEFuag>.
Qin, Li et al. ‘Does Physical Activity Modify the Risk of Obesity for Type 2 Diabetes: A Review of Epidemiological Data’. European Journal of Epidemiology 25.1 (2010): 5–12. Web.
Raskin, P. et al. ‘Initiating Insulin Therapy in Type 2 Diabetes: A Comparison of Biphasic and Basal Insulin Analogs’. Diabetes Care 28.2 (2005): 260–265. Web.
‘Resources and Tools’. N.p., n.d. Web. <http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/78:global-guideline-for-managing-older-people-with-type-2-diabetes.html>.
‘---’. N.p., n.d. Web. <http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/79:global-guideline-for-type-2-diabetes.html>.
‘---’. N.p., n.d. Web. <http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/80:the-global-idf-ispad-guidelines-for-diabetes-in-childhood-and-adolescence.html>.
Richard I. G. Holt, , Clive Cockram, , Allan Flyvbjerg, , and Barry J. Goldstein. Textbook of Diabetes. John Wiley, 2016. Web. <https://ebookcentral-proquest-com.ezproxy4.lib.le.ac.uk/lib/leicester/reader.action?docID=4769056>.
Richter, Bernd, and Gudrun Neises. ‘“Human” Insulin versus Animal Insulin in People with Diabetes Mellitus’. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd, 1996. Web. <http://doi.wiley.com/10.1002/14651858.CD003816.pub2>.
Riddle, M. C. et al. ‘Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-Week, Randomized, Placebo-Controlled Comparison (GetGoal-L)’. Diabetes Care 36.9 (2013): 2489–2496. Web.
Rinki Murphy. ‘Monogenic Diabetes and Pregnancy’. Obstetric Medicine 8.3 (2015): n. pag. Web. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935018/>.
Rizos, Christos V., Anastazia Kei, and Moses S. Elisaf. ‘The Current Role of Thiazolidinediones in Diabetes Management’. Archives of Toxicology 90.8 (2016): 1861–1881. Web.
Rosenstock, J., M. Davies, et al. ‘A Randomised, 52-Week, Treat-to-Target Trial Comparing Insulin Detemir with Insulin Glargine When Administered as Add-on to Glucose-Lowering Drugs in Insulin-Naive People with Type 2 Diabetes’. Diabetologia 51.3 (2008): 408–416. Web.
Rosenstock, J., D. Raccah, et al. ‘Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-Week, Randomized, Open-Label, Active-Controlled Study (GetGoal-X)’. Diabetes Care 36.10 (2013): 2945–2951. Web.
Rotz, M. E. et al. ‘Implications of Incretin-Based Therapies on Cardiovascular Disease’. International Journal of Clinical Practice 69.5 (2015): 531–549. Web.
Ryder, Bob et al. ‘ABCD Position Statement on GLP-1 Based Therapies and Pancreatic Damage’. Practical Diabetes 30.9 (2013): 388–391. Web.
S M Attard. ‘Implications of Iron Deficiency/Anemia on the Classification of Diabetes Using HbA1c’. Nutrition & Diabetes 5.6 (2015): n. pag. Web. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491857/>.
‘Safety and Insulin: Implementation of National Guidance at a Local Level | Journal Content | Diabetesonthenet.Com’. N.p., n.d. Web. <http://www.diabetesonthenet.com/journal-content/view/safety-and-insulin-implementation-of-national-guidance-at-a-local-level>.
Sallis, James F et al. ‘Progress in Physical Activity over the Olympic Quadrennium’. The Lancet 388.10051 (2016): 1325–1336. Web.
Samuel, Varman T., and Gerald I. Shulman. ‘Intergrating Mechanisms for Insulin Resistance: Common Threads and Missing Links’. Cell 148.5 (2012): 852–871. Web.
Schauer, Philip R., Deepak L. Bhatt, et al. ‘Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes’. New England Journal of Medicine 376.7 (2017): 641–651. Web.
Schauer, Philip R., Sangeeta R. Kashyap, et al. ‘Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes’. New England Journal of Medicine 366.17 (2012): 1567–1576. Web.
---. ‘Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes’. New England Journal of Medicine 366.17 (2012): 1567–1576. Web.
Schwartz, Stanley S. et al. ‘The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema’. Diabetes Care 39.2 (2016): 179–186. Web.
Simmons, Rebecca K et al. ‘A Randomised Trial of the Effect and Cost-Effectiveness of Early Intensive Multifactorial Therapy on 5-Year Cardiovascular Outcomes in Individuals with Screen-Detected Type 2 Diabetes: The Anglo–Danish–Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) Study’. Health Technology Assessment 20.64 (2016): 1–86. Web.
Sivasubramaniyam, S., S. A. Amiel, and P. Choudhary. ‘Proportion of Daily Capillary Blood Glucose Readings Required in the Target Range for Target Glycaemic Control: Shift of Focus from Target Range to Proportion in Range’. Diabetic Medicine 34.10 (2017): 1456–1460. Web.
Sjöström, Lars et al. ‘Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery’. New England Journal of Medicine 351.26 (2004): 2683–2693. Web.
Srinivasan, B T et al. ‘Recent Advances in the Management of Type 2 Diabetes Mellitus: A Review’. Postgraduate Medical Journal 84.996 (2008): 524–531. Web.
Srinivasan, Balasubramanian T., and Melanie Davies. ‘Glycaemic Management of Type 2 Diabetes’. Medicine 42.12 (2014): 711–717. Web.
Srinivasan, P et al. ‘Islet Cell Transplantation’. Postgraduate Medical Journal 83.978 (2007): 224–229. Web.
‘Standards of Medical Care in Diabetes--2015: Summary of Revisions’. Diabetes Care 38.Supplement_1 (2015): S4–S4. Web.
Steven, S., and R. Taylor. ‘Restoring Normoglycaemia by Use of a Very Low Calorie Diet in Long- and Short-Duration Type 2 Diabetes’. Diabetic Medicine 32.9 (2015): 1149–1155. Web.
Steven, Sarah et al. ‘Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders’. Diabetes Care 39.5 (2016): 808–815. Web.
Stewart, Zoe A. et al. ‘Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes’. New England Journal of Medicine 375.7 (2016): 644–654. Web.
Swinnen, Sanne G et al. ‘Insulin Detemir versus Insulin Glargine for Type 2 Diabetes Mellitus’. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd, 1996. Web. <http://doi.wiley.com/10.1002/14651858.CD006383.pub2>.
Tanner, Michael. ‘Review: In Type 2 Diabetes, Adding Dipeptidyl Peptidase-4 Inhibitors to Sulphonylureas Increases Hypoglycemia’. Annals of Internal Medicine 165.4 (2016): n. pag. Web.
Tao, L. et al. ‘Cost-Effectiveness of Intensive Multifactorial Treatment Compared with Routine Care for Individuals with Screen-Detected Type 2 Diabetes: Analysis of the ADDITION-UK Cluster-Randomized Controlled Trial’. Diabetic Medicine 32.7 (2015): 907–919. Web.
‘Type 2 Diabetes in Adults: Management | Guidance and Guidelines | NICE’. n. pag. Web. <https://www.nice.org.uk/guidance/ng28>.
Umpierre, Daniel. ‘Physical Activity Advice Only or Structured Exercise Training and Association With HbA Levels in Type 2 Diabetes’. JAMA 305.17 (2011): n. pag. Web.
‘Unit 3 – Special Care Groups: A Practical Guide to Pregnancy Complicated by Diabetes - Diabetes & Primary Care’. N.p., n.d. Web. <http://www.diabetesandprimarycare.co.uk/journal-content/view/unit-3-special-care-groups-a-practical-guide-to-pregnancy-complicated-by-diabetes/?preview>.
Villani, M., B. de Courten, and S. Zoungas. ‘Emergency Treatment of Hypoglycaemia: A Guideline and Evidence Review’. Diabetic Medicine 34.9 (2017): 1205–1211. Web.
Vloemans, A. F. et al. ‘Keeping Safe. Continuous Glucose Monitoring (CGM) in Persons with Type 1 Diabetes and Impaired Awareness of Hypoglycaemia: A Qualitative Study’. Diabetic Medicine 34.10 (2017): 1470–1476. Web.
Wanner, Christoph et al. ‘Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes’. New England Journal of Medicine 375.4 (2016): 323–334. Web.
‘WHO 2011 Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus’. N.p., n.d. Web. <http://www.who.int/diabetes/publications/diagnosis_diabetes2011/en/>.
Yeh, James S., Robert F. Kushner, and Gordon D. Schiff. ‘Obesity and Management of Weight Loss’. New England Journal of Medicine 375.12 (2016): 1187–1189. Web.
Yki-Järvinen, H. et al. ‘Insulin Glargine or NPH Combined with Metformin in Type 2 Diabetes: The LANMET Study’. Diabetologia 49.3 (2006): 442–451. Web.
Young, Laura A, and John B Buse. ‘GLP-1 Receptor Agonists and Basal Insulin in Type 2 Diabetes’. The Lancet 384.9961 (2014): 2180–2181. Web.
Young-Hyman, Deborah et al. ‘Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140’. Diabetes Care 40.2 (2017): 287.1-287. Web.
Zaccardi, Francesco et al. ‘Pathophysiology of Type 1 and Type 2 Diabetes Mellitus: A 90-Year Perspective’. Postgraduate Medical Journal 92.1084 (2016): 63–69. Web.
Zinman, Bernard et al. ‘Insulin Degludec, an Ultra-Long-Acting Basal Insulin, Once a Day or Three Times a Week versus Insulin Glargine Once a Day in Patients with Type 2 Diabetes: A 16-Week, Randomised, Open-Label, Phase 2 Trial’. The Lancet 377.9769 (2011): 924–931. Web.
